Related Experiment Videos
Risk factor levels, risk factor combinations, and residual coronary risk: population-based estimates for secondary
Karl J Krobot1, Alexander Wagner, Uwe Siebert
1MSD Sharp & Dohme, Lindenplatz 1, 85540 Haar, Germany. karl.krobot@msd.de
Insights
Even on high-dose statin therapy, coronary heart disease (CHD) patients in Germany face significant residual risk. Further strategies are needed to lower this risk below the 20% intervention threshold.
Area of Science:
- Cardiology
- Public Health
- Pharmacotherapy
Background:
- Assesses risk factor combinations and residual risks for coronary heart disease (CHD) patients on statins.
- Aims to bridge the gap between clinical trial data and real-world absolute risk.
- Focuses on patients receiving ongoing statin monotherapy.
Purpose of the Study:
- To evaluate residual coronary risk in CHD patients on statin monotherapy in Germany.
- To identify prevalent risk factor combinations contributing to residual risk.
- To project future risk based on current treatment patterns.
Main Methods:
- Retrospective, population-based cross-sectional study using the MediPlus database (2007).
- Included 13,256 CHD patients on statin monotherapy.
- Estimated residual 10-year coronary risk using the Framingham secondary prevention algorithm and generalized estimating equations.
Main Results:
- Overall residual 10-year coronary risk was projected at 35.1%.
- 83.6% of patients had a residual risk of ≥20%, and 36.5% had a risk of ≥40%.
- Increasing statin dosage showed a minimal projected risk reduction.
Conclusions:
- Typical CHD patients on high-dose statin monotherapy exceed the 20% 10-year intervention threshold for residual risk.
- Reducing residual coronary risk without compromising patient safety remains a significant clinical challenge.
- Highlights the need for novel approaches to manage cardiovascular risk in statin-treated patients.
Background:
Population-based risk factor combinations and residual risks for coronary heart disease (CHD) patients on statins were assessed in order to bridge the gap between knowledge on relative effects from clinical trials and absolute risk from real-world practice.
Design:
Population-based, retrospective 1-year cross-sectional primary care study in CHD patients (ICD-10 I20-I25) on ongoing statin monotherapy in Germany in 2007 (MediPlus database, IMS Health).
Methods:
Prevalence charts for 384 risk factor combinations were constructed. Population-averaged residual risks were estimated using the Framingham secondary prevention algorithm and generalized estimating equations accounting for repeated measurements within patients.
Results:
13,256 CHD patients in 332 practices were eligible for the study (7791 men, 5465 women, 32.6% with diabetes mellitus, 82.5% on simvastatin at a mean effective dose of 26.7 mg/d). The overall residual 10-year coronary risk was projected at 35.1% (robust 95% CI 34.8-35.4). In 83.6% of patients this risk was ≥20% and in 36.5% of patients the risk was ≥40%. An increase in tablet strength to 40 mg (fluvastatin 80 mg) and in exposure to 40 mg/d (fluvastatin 80 mg/d) would be expected to reduce the predicted residual 10-year coronary risk to 34.1% and 33.8%, respectively.
Conclusion:
Even when receiving high-dose statin monotherapy, the typical CHD patient in Germany is projected to be exposed to a residual coronary risk that is substantially above the generally recognized intervention threshold of 20% over 10 years. The question of how to further reduce residual coronary risk without compromising patient safety in patients on optimal statin therapy remains an important clinical challenge.
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:26Atherosclerosis III: Management
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:27Coronary Artery Disease V: Interprofessional Care
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents